Lycia Therapeutics (NASDAQ:LYCA) Research Coverage Started at Evercore

Evercore began coverage on shares of Lycia Therapeutics (NASDAQ:LYCA – Free Report) in a research note released on Tuesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $43.00 price target on the stock.

Other analysts have also issued reports about the stock. Wall Street Zen upgraded shares of Lycia Therapeutics to a “hold” rating in a research note on Saturday, October 31st. Jefferies Financial Group assumed coverage on shares of Lycia Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $50.00 price target for the company. Five investment analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $54.00.

Read Our Latest Research Report on Lycia Therapeutics

Lycia Therapeutics Stock Performance

Shares of LYCA opened at $31.77 on Tuesday. Lycia Therapeutics has a 1 year low of $22.19 and a 1 year high of $36.49.

Insider Buying and Selling at Lycia Therapeutics

In related news, major shareholder Venrock Healthcare Capital Par acquired 8,305 shares of Lycia Therapeutics stock in a transaction dated Monday, November 2nd. The stock was acquired at an average price of $26.95 per share, for a total transaction of $223,819.75. Following the transaction, the insider owned 6,858,542 shares of the company’s stock, valued at $184,837,706.90. This represents a 0.12% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders have purchased 2,078,749 shares of company stock worth $38,526,342.

Lycia Therapeutics Company Profile

(Get Free Report)

Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.

Further Reading

Analyst Recommendations for Lycia Therapeutics (NASDAQ:LYCA)

Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.